Mitomycin C and decarbamoyl mitomycin C induce p53-independent p21^{WAF1/CIP1} activation

SHU-YUAN CHENG\textsuperscript{1,2*}, JIWON SEO\textsuperscript{1}, BIK TZU HUANG\textsuperscript{1}, TANYA NAPOLITANO\textsuperscript{1} and ELISE CHAMPEIL\textsuperscript{1,2*}

\textsuperscript{1}Department of Sciences, John Jay College of Criminal Justice, City University of New York, NY 10019;  
\textsuperscript{2}Graduate Center of the City University of New York, New York, NY 10016, USA

Received April 29, 2016; Accepted August 16, 2016

DOI: 10.3892/ijo.2016.3703

Abstract. Mitomycin C (MC), a commonly used anticancer drug, induces DNA damage via DNA alkylation. Decarbamoyl mitomycin C (DMC), another mitomycin lacking the carbamate at C10, generates similar lesions as MC. Interstrand cross-links (ICLs) are believed to be the lesions primarily responsible for the cytotoxicity of MC and DMC. The major ICL generated by MC (α-ICL) has a trans stereochemistry at the guanine-drug linkage whereas the major ICL from DMC (β-ICL) has the opposite, cis, stereochemistry. In addition, DMC can provoke strong p53-independent cell death. Our hypothesis is that the stereochemistry of the major unique β-ICL generated by DMC is responsible for this p53-independent cell death signaling. p53 gene is inactively mutated in more than half of human cancers. p21^{WAF1/CIP1}, known as a major effector of p53 is involved in p53-dependent and -independent cell death. This study revealed the role of p21^{WAF1/CIP1} on MC and DMC triggered cell damage. MCF-7 (p53-proficient) and K562 (p53-deficient) cells were used. Cell cycle distributions were shifted to the S phase in MCF-7 treated with MC and DMC, but were shifted to the S phase in K562. p21^{WAF1/CIP1} activation was observed in both cells treated with MC and DMC, and DMC triggered more significant activation. Knocking down p53 in MCF-7 did not attenuate MC and DMC induced p21^{WAF1/CIP1} activation. The α-ICL itself was enough to cause p21^{WAF1/CIP1} activation.

Introduction

Mitomycin C (MC) is a bioreductive anticancer drug produced by Streptomyces caespitosus (1,2) and commonly used to treat many cancers, such as stomach, anal, and lung cancers (3,4). However, the response rates are only ~15-20% (4). Although its mode of action has been extensively examined (5), it is still the center of numerous research endeavors (6-10). In particular, this drug is used intensively to investigate the mechanisms involved in DNA repair (8-10). Studies showed that mitomycin C induces DNA damage via DNA alkylation to produce DNA mono-adducts, intrastrand cross-links and interstrand cross-links (ICLs) (10,11). The main toxicity of MC is due to these interstrand MC-DNA crosslinks (12).

The MC analog, 10-decarbamoyl mitomycin C (DMC), has not been fully investigated. It has recently been found that the major ICLs produced by MC and DMC have opposite stereochemistry. MC generates an ICL with trans stereochemistry (α-ICL) and DMC generates an ICL with cis stereochemistry (β isomer, β-ICL) (Fig. 1). Experimental evidence points to crosslinks α-ICL and β-ICL as the lesions primarily responsible for the cytotoxicity of the mitomycins (13). When the cellular and molecular response of human cancer cells treated with MC and DMC were compared, it was found that DMC was more toxic in human cancer cells with or without a functioning p53 (14) and that DMC provokes a strong p53-independent cell death (7). Xiao et al (15) further suggested that DMC could enhance Chk1 checkpoint activation and Rad51 chromatin recruitment via a p53-independent disassociation of ATR chromatin eviction.

The study of anticancer drug induced DNA damage mechanisms has mainly focused on cell cycle and checkpoint control proteins. However, there are other mechanisms which can regulate cell cycle progression, such as p21^{WAF1/CIP1}. Esposito et al (16) demonstrated that nucleolar stressors, 5-flouracil (5-FU) and oxaliplatin (L-OHP), trigger cell cycle arrest and apoptosis by altering rpl3-regulated p21 expression. Moreover, this alteration of p21 expression by rpl3 could occur in a p53-independent manner (17). In many human cancers, abnormal expressions of cyclin D1 and cyclin E (which can promote the transition of G1/S phase) have been observed (18). This accelerated G1/S transition effect triggered by cyclin D1 and cyclin E can be inhibited by p21^{WAF1/CIP1} when anticancer drugs induce DNA damage (19,20). Choi

Abbreviations: MC, mitomycin C; DMC, 10-decarbamoyl mitomycin C; α-ICL, α interstrand cross-link

Key words: mitomycin C, decarbamoyl mitomycin C, p21, p53
et al (20) observed that MC inhibited the G1/S transition by p53-dependent p21<sup>WAF1/CIP1</sup>, but at sublethal MC concentrations, the accumulation of cyclin E with a delayed increase of p21<sup>WAF1/CIP1</sup> promoted G1/S transition. It suggests that the cell cycle G1/S transition is controlled by cyclin E and p21<sup>WAF1/CIP1</sup> in a MC dose-dependent manner.

The p53 tumor suppressor protein is one of the key players for keeping genetic stability following DNA damage and is the target of many chemotherapeutic drugs (21,22). However, p53 gene is inactively mutated in more than half of human cancers (22-24). p21<sup>WAF1/CIP1</sup> , known as a protein cyclin-dependent kinase inhibitor, is a major effector of p53 and is involved in p53-dependent and -independent control of cell proliferation and death (25). p21<sup>WAF1/CIP1</sup> expression has been linked with irreversible cell cycle arrest in both G1 and G2/M. In this study, MCF-7 (p53-proficient cell line) and K562 (p53-deficient cell line) were used to elucidate the role of p21<sup>WAF1/CIP1</sup> in the signaling mechanism of MC and DMC and their effects on cell cycle. An oligonucleotide (18 mer) bearing the major MC-ICL (α-ICL) was also synthesized and transfected into cells to unveil the effect of the α-ICL on the regulation of p21<sup>WAF1/CIP1</sup>.

Materials and methods

Cell culture and reagents. Human breast cancer cells (MCF-7) and leukemia cancer cells (K562) were obtained from the American Type Tissue Culture (Manassas, VA, USA). Both cell lines have been used for mitomycin C studies (7,26). MCF-7 cell line is a p53-proficient cell line. K562 cell line is a p53-deficient cell line with an inactivation mutation in exon 5 (27). Dulbecco’s modiﬁed Eagle’s medium (DMEM), RPM1-1640, fetal bovine serum (FBS), heat-inactivated horse serum, gentamicin (50 mg/ml) were obtained from Invitrogen (Gaithersburg, MD, USA). MCF-7 cells were cultured within DMEM supplemented with 10% FBS and 50 µg/ml gentamicin. K562 cells were cultured within RPM1-1640 supplemented with 10% FBS, 2 mM glutamine and 50 µg/ml gentamicin. Both cells were maintained in a humidified atmosphere at 37°C and 5% CO<sub>2</sub>. For chemical treatment, cells were cultured in 60-mm Petri dishes one day prior to the experiment. Cells were grown until medium density (~80% confluence) before chemical treatments.

Mitomycin C was a generous gift from Dr Maria Tomasz (Hunter College, City University of New York, New York, USA). Decarbamoyl mitomycin C was synthesized based on the protocol of Kinoshita et al (28).

β-actin antibody was obtained from Sigma-Aldrich (St. Louis, MO, USA). p145 p21<sup>WAF1/CIP1</sup> and p146 p21<sup>WAF1/CIP1</sup> antibodies were from Santa Cruz. Bio-Rad DC (detergent compatible) protein assay reagents were purchased from Bio-Rad (Hercules, CA, USA). The Super Signal West Pico chemiluminescent kit, secondary antibodies containing anti-rabbit IgG or anti-mouse IgG conjugated to horseradish peroxidase, mammalian protein extraction reagent (M-PER) lysis buffer, Halt protease inhibitor cocktail, and stripping buffer were obtained from Pierce (Rockford, IL, USA). SuperFect™ transfection reagent was purchased from Qiagen (Valencia, CA, USA). All other reagents were purchased from Sigma-Aldrich.

Cell culture and reagents. Human breast cancer cells (MCF-7) and leukemia cancer cells (K562) were obtained from the American Type Tissue Culture (Manassas, VA, USA). Both cell lines have been used for mitomycin C studies (7,26). MCF-7 cell line is a p53-proficient cell line. K562 cell line is a p53-deficient cell line with an inactivation mutation in exon 5 (27). Dulbecco’s modiﬁed Eagle’s medium (DMEM), RPM1-1640, fetal bovine serum (FBS), heat-inactivated horse serum, gentamicin (50 mg/ml) were obtained from Invitrogen (Gaithersburg, MD, USA). MCF-7 cells were cultured within DMEM supplemented with 10% FBS and 50 µg/ml gentamicin. K562 cells were cultured within RPM1-1640 supplemented with 10% FBS, 2 mM glutamine and 50 µg/ml gentamicin. Both cells were maintained in a humidified atmosphere at 37°C and 5% CO<sub>2</sub>. For chemical treatment, cells were cultured in 60-mm Petri dishes one day prior to the experiment. Cells were grown until medium density (~80% confluence) before chemical treatments.

Mitomycin C was a generous gift from Dr Maria Tomasz (Hunter College, City University of New York, New York, USA). Decarbamoyl mitomycin C was synthesized based on the protocol of Kinoshita et al (28).

β-actin antibody was obtained from Sigma-Aldrich (St. Louis, MO, USA). p145 p21<sup>WAF1/CIP1</sup> and p146 p21<sup>WAF1/CIP1</sup> antibodies were from Santa Cruz. Bio-Rad DC (detergent compatible) protein assay reagents were purchased from Bio-Rad (Hercules, CA, USA). The Super Signal West Pico chemiluminescent kit, secondary antibodies containing anti-rabbit IgG or anti-mouse IgG conjugated to horseradish peroxidase, mammalian protein extraction reagent (M-PER) lysis buffer, Halt protease inhibitor cocktail, and stripping buffer were obtained from Pierce (Rockford, IL, USA). SuperFect™ transfection reagent was purchased from Qiagen (Valencia, CA, USA). All other reagents were purchased from Sigma-Aldrich.
corresponding horseradish peroxidase-linked secondary antibody. Blots were developed using Super Signal West Pico Chemiluminescent Substrate detection reagents. Membranes were then stripped with stripping buffer for 15 min at room temperature and re-probed with β-actin (1 µg/µl) or p21\(^{\text{WAF1/CIP1}}\) antibody as the loading control. Chemiluminescent signals were captured using the Geliance 600 imaging system (Perkin-Elmer, Shelton, CT, USA) and analyzed by GeneTools software (Syngene, Frederick, MD, USA).

**Transfection.** p53 shRNA plasmid from Santa Cruz was transiently transfected into MCF-7 cells to knock down the expression of p53 by using SuperFect™ transfection reagent 24 h before chemical treatments. Briefly, p53 shRNA plasmid was mixed with SuperFect in a ratio of 1 µg DNA to 2 µl transfection reagent according to the manufacturer’s instructions. The mixtures were added in 30 µl of serum-free DMEM for 10 min at room temperature. The mixtures were then mixed with 0.6 ml of complete cell culture media and transferred to the cells for a 3-h incubation at 37°C in humidified air containing 5% CO\(_2\). The transfection mixtures were then removed and replaced with fresh media after washing the cells twice with PBS. The cells were then incubated for an additional 24 h at 37°C in humidified air containing 5% CO\(_2\) prior to chemical treatments.

The isolated α-interstrand cross-link was also transfected into cells by SuperFect transfection reagent using the same protocol as p53 shRNA plasmid transfection.

**Statistical analyses.** All experiments were performed at least in triplicate, and results are reported as means ± SEM. Statistical significance was determined using one-way analysis of variance (ANOVA) followed by Dunnett’s post hoc test (p<0.05, with control at 100%) by using GraphPad PRISM® 6 software.

**Results**

**Cell cycle distribution patterns of MCF-7 and K562 cells treated with MC and DMC are shifted to G1/S phase and to S phase, respectively.** DNA content distribution profiles of MCF-7 treated with various concentrations of MC and DMC for 24 h are shown in Fig. 2 and Tables I and II. The cell cycle pattern of MCF-7 control cells appeared normal, with most cells halted at the G1/G0 phase (49.4% cell population at G1/G0 phase, 10.1% at S phase and 32.6% at G2/M phase). MC exposure induced a shift of MCF-7 cell cycle distribution pattern from G2/M to G1/S phase as MC concentration increased. When MCF-7 cells were treated with 50 µM and 75 µM of MC, >90% of cells halted at the G1/S phase (Fig. 2, left panel and Table I). These results concur with previous studies which suggest that MC shifts cell cycles to G1/S or S phase (30,31). DMC exposure also induced a shift of MCF-7 cell cycle distribution pattern from G2/M to G1/S as DMC concentration increased (Fig. 2, right panel and Table II). Furthermore, DMC induced a shift to G1/S (43.5±39.5% = 83%) at the concentration as low as 5 µM and at lower concentration range as compared to MC.

For K562 cells, DNA content distribution profiles of cells treated with various concentrations of MC and DMC for 24 h are shown in Fig. 3 and Table III and IV. Most of K562 control
Figure 2. Effects of MC and DMC on cell cycle of MCF-7 cells. MCF-7 cells (1.0x10^6 per well) were plated and treated with vehicle (cell culture media), MC and DMC for 24 h. After chemical treatments, cells were stained with 50 μg/ml propidium iodide and analyzed for cell cycle distribution patterns by flow cytometer. Cell cycle distribution patterns of MCF-7 are shifted to G1/S phase after chemical exposures.
Figure 3. Effects of MC and DMC on cell cycle of K562 cells. K562 cells (1.0x10⁶ per well) were plated and treated with vehicle (cell culture media), MC and DMC for 24 h. After chemical treatments, cells were stained with 50 µg/ml propidium iodide and analyzed for cell cycle distribution patterns by flow cytometry. Cell cycle distribution patterns of K562 cells are shifted to S phase after chemical exposures.
cells were halted at the G2/M phase (41.4% of the cell population at G1/G0 phase, 4.2% at S phase and 52.5% at G2/M phase). MC exposure increased cells halted at the S phase for cells treated with 50 µM and 100 µM MC (Fig. 3, left panel and Table III). The cell population of K562 at G2/M was also reduced at 50 and 100 µM. DMC exposure not only increased cells halted in the S phase, but also decreased cells arrested in the G1/G0 phase as DMC concentration increased (Fig. 3, right panel and Table IV). DMC exposure increased cells halted at the S phase at as low as 5 µM and at lower concentration range as compared to MC.

p21WAF1/CIP1 in MCF-7 and K562 cells is activated by MC and DMC. p21WAF1/CIP1 has been linked with irreversible cell cycle arrest in both G1 and G2/M. Phosphorylation of p21WAF1/CIP1 at Thr145 (p145-p21) induces its cytoplasmic accumulation to promote cell proliferation (32). In addition, phosphorylation of p21WAF1/CIP1 at Ser146 (p146-p21) leads to the stability of p21WAF1/CIP1 and cell survival (33). Dephosphorylation of p21WAF1/CIP1 will increase the translocation of active p21WAF1/CIP1 to nuclei and subsequently trigger gene expression for cell proliferation suppression. In order to study the p21WAF1/CIP1 activation, the levels of phosphorylated p21WAF1/CIP1 at Thr145 (p145-p21) and at Ser146 (p146-p21) in MCF-7 cells treated with MC and DMC for 24 h were determined by western blot analysis. p21WAF1/CIP1 expression was also measured as the loading control. The integrated density values (IDV) of western blot images were normalized with the IDV of the corresponding p21WAF1/CIP1 images. The final data for all chemically treated groups were expressed as a percentage of the control data. The data of control samples were taken as 100%. (A) p145-p21, *p<0.05, **p<0.01; (B) p146-p21, there was no statistical difference between the groups.

Figure 4. Effects of MC and DMC on p21WAF1/CIP1 activation in MCF-7 cells. The relative levels of phosphorylated p21WAF1/CIP1 at Thr145 (p145-p21) and at Ser146 (p146-p21) in MCF-7 cells treated with MC and DMC for 24 h were determined by western blot analysis. p21WAF1/CIP1 expression was also measured as the loading control. The integrated density values (IDV) of western blot images were normalized with the IDV of the corresponding p21WAF1/CIP1 images. The final data for all chemically treated groups were expressed as a percentage of the control data. The data of control samples were taken as 100%. (A) p145-p21, *p<0.05, **p<0.01; (B) p146-p21, there was no statistical difference between the groups.

### Table III. Cell cycle profiles of K562 treated with various concentrations of mitomycin C (MC) for 24 h.

| Concentration of MC | G1/G0 (%) | S (%) | G2/M (%) |
|---------------------|-----------|-------|----------|
| Control             | 41.4      | 4.2   | 52.5     |
| 5 µM                | 33.9      | 6.0   | 53.1     |
| 10 µM               | 47.2      | 3.8   | 46.1     |
| 50 µM               | 40.5      | 13.1  | 43.5     |
| 75 µM               | 42.8      | 18.8  | 35.2     |

### Table IV. Cell cycle profiles of K562 treated with various concentrations of 10-decarbamoyl mitomycin C (DMC) for 24 h.

| Concentration of DMC | G1/G0 (%) | S (%) | G2/M (%) |
|----------------------|-----------|-------|----------|
| Control              | 41.4      | 4.2   | 52.5     |
| 5 µM                 | 40.8      | 9.7   | 47.0     |
| 10 µM                | 34.8      | 12.5  | 50.2     |
| 50 µM                | 30.6      | 10.0  | 57.8     |
| 75 µM                | 33.9      | 17.5  | 48.1     |

For K562 cells, MC and DMC significantly reduced the level of phosphorylated p21WAF1/CIP1 at Thr145 (p145-p21) in MCF-7 cells exposed with the dosage as low as 5 µM (Fig. 4A). DMC at 5 µM reduced more p145-p21 in MCF-7 cells as compared with cells treated with 5 µM MC. However, there was no significant statistical change on the level of phosphorylation of p21WAF1/CIP1 at Ser146 (p146-p21) in MCF-7 cells treated with MC and DMC for 24 h (Fig. 4B).

For K562 cells, MC and DMC significantly reduced the level of phosphorylated p21WAF1/CIP1 at Thr145 (p145-p21) in K562 cells treated with 50 µM and 75 µM of chemicals for 24 h (Fig. 5A). The level of phosphorylated p21WAF1/CIP1 at Ser146 (p146-p21) was only significantly decreased when K562 cells were treated with 75 µM of DMC for 24 h (Fig. 5B). DMC at 75 µM reduced more p146-p21 in K562 cells as compared with cells treated with 75 µM MC.
Activation of p21\(^\text{WAF1/CIP1}\) by MC and DMC in MCF-7 is p53-independent. p53 shRNA plasmid was transfected into MCF-7 cells 24 h prior to MC and DMC exposures. (A) Expression level of p53 in MCF-7 cells and p53 knockdown cells were detected by western blot analysis. Representative blot is shown. (B) p53 knock-down MCF-7 cells were treated with MC and DMC for 24 h. The relative levels of phosphorylated p21\(^\text{WAF1/CIP1}\) at Thr145 (p145-p21) were determined by western blot analysis. p21\(^\text{WAF1/CIP1}\) expression was also measured as the loading control. The integrated density values (IDV) of western blot images were normalized with the IDV of the corresponding p21\(^\text{WAF1/CIP1}\) images. The final data for all chemically treated groups were expressed as a percentage of the control data. The data of control samples were taken as 100%. \(\ast p<0.05\).
MC and DMC also regulate cell cycle by different mechanisms to cause cell cycle arrest at different phases (20,34). MC at 5 µM has been known to trigger cell cycle arrest at S phase in human hepatocellular carcinoma cells, HepG2 (p53 wild-type cells) and Hep3B (p53 null cells) (20). Boamah et al (34) also demonstrated that 1 µM DMC halted cell proliferation at the S and G2/M phases and MC at 10 µM arrested cells at S phase in p53-null DLD1 colon cancer cells. The present cell cycle analysis is in agreement with those studies and showed that both MC and DMC increased the cell population at the G1/S phase in MCF-7 (p53 wild-type) cells and at the S phase in K562 (p53-deficient) cells. p53, also known as cell cycle check protein, can mediate a G1 arrest to preserve the genetic stability under DNA damage (35). p53 deficiency in K562 could possibly lead cells to lose the regulation of G1 progression. Thus, there was no significant change on G1 phase cell population observed in this study.

Abbas et al (7) and Boamah et al (34) indicated that DMC triggers stronger p53-independent cell damage. This suggests that another signaling pathway besides p53 could be responsible for DMC induced cell death. p21WAF1/CIP1 is a p53 downstream effector and inhibits the G1-S transition. However, p21WAF1/CIP1 expression can also be regulated by a p53-independent mechanism (36). p21WAF1/CIP1 has been shown to be upregulated in ML-1 p53 wild-type cells by MC and DMC (7) and in HepG2 p53 wild-type cells by MC (20). In this study, the status of p21WAF1/CIP1 activation induced by MC and DMC in MCF-7 and K562 cells was measured by the level of phosphorylated p21WAF1/CIP1. Dephosphorylation of p21WAF1/CIP1 will activate p21WAF1/CIP1 and translocate p21WAF1/CIP1 to nuclei. Our results showed that p21WAF1/CIP1 was dephosphorylated by MC and DMC in both MCF-7 and K562 cells. DMC showed stronger p21WAF1/CIP1 activation as compared to MC.

Since p21WAF1/CIP1 can be regulated by p53-dependent and -independent mechanisms (36) and p21WAF1/CIP1 was also activated in K562 (p53 deficient) cells after MC and DMC exposures, it is possible that p21WAF1/CIP1 activation by MC and DMC in MCF-7 could be regulated by a p53-independent pathway. Russo et al (17) and Esposito et al (16) suggested p21WAF1/CIP1 regulates cell cycle arrest and apoptosis in a p53-independent mechanism in response to ribosome protein rpL3. In this study, p53 shRNA knockdown did lower the expression of p53 in MCF-7, but did not attenuate MC and DMC induced p21WAF1/CIP1 dephosphorylation. This indicates that activation of p21WAF1/CIP1 in MCF-7 cells by MC and DMC did not require p53. DNA lesions formed by MC and DMC have been linked to their cytotoxic mechanisms. In this study, the major DNA lesion of MC (α-ICL) was introduced into MCF-7 cells. The activation of p21WAF1/CIP1 was observed to a similar extent when compared to cells treated with MC and DMC. However, there was no significant change in cell cycle distribution pattern after the α-ICL was introduced into MCF-7 cells when compared with DNA duplex control. This indicates that the α-ICL itself is sufficient to trigger p21WAF1/CIP1 activation, but not to set the cell cycle at rest. Several reasons may explain this phenomenon. ICLs are extremely toxic to cells (37). MC generates a total of 6 different covalent DNA lesions (38,39) and other DNA adducts that are not examined in this study may contribute to MC-induced cell cycle arrest. Secondly, the transfected oligonucleotide bearing the ICL may...
not set the cell cycle at rest because it is not part of a replicating machinery i.e., DNA itself or part of a replicating plasmid. Moreover, another CIP/KIP family member, p27, could play a role in this regulation. p27 is also a cyclin-dependent kinase inhibitor as p21WAF1/CIP1 and has similar cellular function as p21WAF1/CIP1. Rao et al (40) demonstrated that p21WAF1/CIP1 and p27 are involved in lovastatin triggered G1 cell cycle arrest in a p53-independent manner. Therefore, it would be of interest to compare p27 expression in response to MC, DMC, and ICLs in cells with or without functioning p53.

In conclusion, mitomycin C and its derivative 10-decarbamoyl mitomycin C triggered cell cycle arrest at G1/S phase in MCF-7 cells and at S phase in K562 cells. DMC induced the arrest at lower concentrations as compared with MC. MC and DMC both decreased the phosphorylated p21WAF1/CIP1 at Thr145 in MCF-7 and K562 cells. DMC showed stronger effect on dephosphorylation of p21WAF1/CIP1 at Thr145 in MCF-7 cells and at S phase in K562 cells. DMC induced another CiP/KiP family member, p27, could play a role in this regulation. p27 is also a cyclin-dependent kinase inhibitor as p21WAF1/CIP1 and has similar cellular function as p21WAF1/CIP1. This study demonstrated that MC and DMC activated p21WAF1/CIP1 in p53-independent manner and α-ICL can trigger the activation of p21WAF1/CIP1. In the future, p21WAF1/CIP1 and other p53-independent signaling pathways in response to the β-ICL will require further investigation.

Acknowledgements

This study was supported by NIH grant 5SC3GM105460 and the PRISM program at John Jay. Special thanks to John Jay College of Criminal Justice Start-up Fund, PRISM fund, and PSC CUNY grant. PRISM is the Program for Research Initiatives for Science Majors at John Jay College and funded by the Title V, HSI-STEM and MSEIP programs within the US Department of Education; the PAESMEM program through the National Science Foundation; and New York State’s Graduate Research and Teaching Initiative.

References

1. Hata T, Hoshi T, Kanamori K, Matsumae A, Sano Y, Shima T and Sugawara R: Mitomycin C, a new antibiotic from Streptomyces. I. J Antibiot (Tokyo) 9: 141-146, 1956.
2. Sartorelli AC, Hodnick WF, Belcourt MF, Tomasz M, Haffty B, Fischer JJ and Rockwell S: Mitomycin C: A prototype bioreductive agent. Oncol Res 6: 501-508, 1994.
3. Verweij J and Pinedo H: Cancer Chemotherapy and Biological Response Modifiers, Annual 11. Pinedo HM, Chabner BA and Longo DL (eds). Vol. 67. Elsevier Science Publishers B.V., Amsterdam, 1990.
4. Bradner WE: Mitomycin C: A clinical update. Cancer Treat Rev 27: 35-50, 2001.
5. Borowy-Borowski H, Lipman R and Tomasz M: Recognition between mitomycin C and specific DNA sequences for cross-link formation. Biochemistry 29: 2999-3006, 1990.
6. Boamah EK, White DE, Talbott KE, Arva NC, Berman D, Tomasz M and Bargonetti J: Mitomycin-DNA adducts induce p53-dependent and p53-independent cell death pathways. ACS Chem Biol 2: 399-407, 2007.
7. Abbas T, Olivier M, Lopez J, Houser S, Xiao G, Kumar GS, Tomasz M and Bargonetti J: Differential activation of p53 by the various adducts of mitomycin C. J Biol Chem 277: 40513-40519, 2002.
8. Ben-Yehoyada M, Wang LC, Kozekov ID, Rizzo CJ, Gottesman ME and Gaultier J: Checkpoint signaling from a single DNA interstrand crosslink. Mol Cell 35: 704-715, 2009.
30. Zhou QM, Wang XF, Liu XJ, Zhang H, Lu YY and Su SB: Curcumin enhanced antiproliferative effect of mitomycin C in human breast cancer MCF-7 cells in vitro and in vivo. Acta Pharmacol Sin 32: 1402-1410, 2011.
31. Yu J, Zhao L, Li Y, Li N, He M, Bai X, Yu Z, Zheng Z, Mi X, Wang E, et al: Silencing of Fanconi anemia complementation group F exhibits potent chemosensitization of mitomycin C activity in breast cancer cells. J Breast Cancer 16: 291-299, 2013.
32. Rössig L, Jadidi AS, Urbich C, Badorff C, Zeiher AM and Dimmeler S: Akt-dependent phosphorylation of p21(Cip1) regulates PCNA binding and proliferation of endothelial cells. Mol Cell Biol 21: 5644-5657, 2001.
33. Li Y, Dowbenko D and Lasky LA: AKT/PKB phosphorylation of p21(Cip1/WAF1) enhances protein stability of p21(Cip1/WAF1) and promotes cell survival. J Biol Chem 277: 11352-11361, 2002.
34. Boamah EK, Brekman A, Tomasz M, Myeku N, Figueiredo-Pereira M, Hunter S, Meyer J, Bhosle RC and Bargonetti J: DNA adducts of decarbamoyl mitomycin C efficiently kill cells without wild-type p53 resulting from proteasome-mediated degradation of checkpoint protein 1. Chem Res Toxicol 23: 1151-1162, 2010.
35. Di Leonardo A, Linke SP, Clarkin K and Wahl GM: DNA damage triggers a prolonged p53-dependent G1 arrest and long-term induction of Cip1 in normal human fibroblasts. Genes Dev 8: 2540-2551, 1994.
36. Macleod KF, Sherry N, Hannon G, Beach D, Tokino T, Kinzler K, Vogelstein B and Jacks T: p53-dependent and independent expression of p21 during cell growth, differentiation, and DNA damage. Genes Dev 9: 935-944, 1995.
37. Lawley PD and Phillips DH: DNA adducts from chemotherapeutic agents. Mutat Res 355: 13-40, 1996.
38. Bargonetti J, Champeil E and Tomasz M: Differential toxicity of DNA adducts of mitomycin C. J Nucleic Acids 2010: 698960, 2010.
39. Tomasz M: Mitomycin C: Small, fast and deadly (but very selective). Chem Biol 2: 575-579, 1995.
40. Rao S, Lowe M, Herliczek TW and Keyomarsi K: Lovastatin mediated G1 arrest in normal and tumor breast cells is through inhibition of CDK2 activity and redistribution of p21 and p27, independent of p53. Oncogene 17: 2393-2402, 1998.